Cargando…

Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma

Adrenacarcinomas are rare, and hypoglycemic syndrome resulting from the secretion of insulin-like growth factor II (IGF-II) by these tumors have been described infrequently. This study describes the case of a young woman with severe persistent hypoglycemia and a large adrenal tumor and discusses the...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchetti, Katia Regina, Pereira, Maria Adelaide Albergaria, Lichtenstein, Arnaldo, Paiva, Edison Ferreira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097138/
https://www.ncbi.nlm.nih.gov/pubmed/27857836
http://dx.doi.org/10.1530/EDM-16-0101
_version_ 1782465561579487232
author Marchetti, Katia Regina
Pereira, Maria Adelaide Albergaria
Lichtenstein, Arnaldo
Paiva, Edison Ferreira
author_facet Marchetti, Katia Regina
Pereira, Maria Adelaide Albergaria
Lichtenstein, Arnaldo
Paiva, Edison Ferreira
author_sort Marchetti, Katia Regina
collection PubMed
description Adrenacarcinomas are rare, and hypoglycemic syndrome resulting from the secretion of insulin-like growth factor II (IGF-II) by these tumors have been described infrequently. This study describes the case of a young woman with severe persistent hypoglycemia and a large adrenal tumor and discusses the physiopathological mechanisms involved in hypoglycemia. The case is described as a 21-year-old woman who presented with 8 months of general symptoms and, in the preceding 3 months, with episodes of mental confusion and visual blurring secondary to hypoglycemia. A functional assessment of the adrenal cortex revealed ACTH-independent hypercortisolism and hyperandrogenism. Hypoglycemia, hypoinsulinemia, low C-peptide and no ketones were also detected. An evaluation of the GH–IGF axis revealed GH blockade (0.03; reference: up to 4.4 ng/mL), greatly reduced IGF-I levels (9.0 ng/mL; reference: 180–780 ng/mL), slightly reduced IGF-II levels (197 ng/mL; reference: 267–616 ng/mL) and an elevated IGF-II/IGF-I ratio (21.9; reference: ~3). CT scan revealed a large expansive mass in the right adrenal gland and pulmonary and liver metastases. During hospitalization, the patient experienced frequent difficult-to-control hypoglycemia and hypokalemia episodes. Octreotide was ineffective in controlling hypoglycemia. Due to unresectability, chemotherapy was tried, but after 3 months, the patient’s condition worsened and progressed to death. In conclusion, our patient presented with a functional adrenal cortical carcinoma, with hyperandrogenism associated with hypoinsulinemic hypoglycemia and blockage of the GH–IGF-I axis. Patient’s data suggested a diagnosis of hypoglycemia induced by an IGF-II or a large IGF-II-producing tumor (low levels of GH, greatly decreased IGF-I, slightly decreased IGF-II and an elevated IGF-II/IGF-I ratio). LEARNING POINTS: Hypoglycemyndrome resulting from the secretion of insulin-like growth factor II (IGF-II) by adrenal tumors is a rare condition. Hypoinsulinemic hypoglycemia associated with hyperandrogenism and blockage of the GH–IGF-I axis suggests hypoglycemia induced by an IGF-II or a large IGF-II-producing tumor. Hypoglycemia in cases of NICTH should be treated with glucocorticoids, glucagon, somatostatin analogs and hGH.
format Online
Article
Text
id pubmed-5097138
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-50971382016-11-17 Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma Marchetti, Katia Regina Pereira, Maria Adelaide Albergaria Lichtenstein, Arnaldo Paiva, Edison Ferreira Endocrinol Diabetes Metab Case Rep Insight into Disease Pathogenesis or Mechanism of Therapy Adrenacarcinomas are rare, and hypoglycemic syndrome resulting from the secretion of insulin-like growth factor II (IGF-II) by these tumors have been described infrequently. This study describes the case of a young woman with severe persistent hypoglycemia and a large adrenal tumor and discusses the physiopathological mechanisms involved in hypoglycemia. The case is described as a 21-year-old woman who presented with 8 months of general symptoms and, in the preceding 3 months, with episodes of mental confusion and visual blurring secondary to hypoglycemia. A functional assessment of the adrenal cortex revealed ACTH-independent hypercortisolism and hyperandrogenism. Hypoglycemia, hypoinsulinemia, low C-peptide and no ketones were also detected. An evaluation of the GH–IGF axis revealed GH blockade (0.03; reference: up to 4.4 ng/mL), greatly reduced IGF-I levels (9.0 ng/mL; reference: 180–780 ng/mL), slightly reduced IGF-II levels (197 ng/mL; reference: 267–616 ng/mL) and an elevated IGF-II/IGF-I ratio (21.9; reference: ~3). CT scan revealed a large expansive mass in the right adrenal gland and pulmonary and liver metastases. During hospitalization, the patient experienced frequent difficult-to-control hypoglycemia and hypokalemia episodes. Octreotide was ineffective in controlling hypoglycemia. Due to unresectability, chemotherapy was tried, but after 3 months, the patient’s condition worsened and progressed to death. In conclusion, our patient presented with a functional adrenal cortical carcinoma, with hyperandrogenism associated with hypoinsulinemic hypoglycemia and blockage of the GH–IGF-I axis. Patient’s data suggested a diagnosis of hypoglycemia induced by an IGF-II or a large IGF-II-producing tumor (low levels of GH, greatly decreased IGF-I, slightly decreased IGF-II and an elevated IGF-II/IGF-I ratio). LEARNING POINTS: Hypoglycemyndrome resulting from the secretion of insulin-like growth factor II (IGF-II) by adrenal tumors is a rare condition. Hypoinsulinemic hypoglycemia associated with hyperandrogenism and blockage of the GH–IGF-I axis suggests hypoglycemia induced by an IGF-II or a large IGF-II-producing tumor. Hypoglycemia in cases of NICTH should be treated with glucocorticoids, glucagon, somatostatin analogs and hGH. Bioscientifica Ltd 2016-11-04 2016 /pmc/articles/PMC5097138/ /pubmed/27857836 http://dx.doi.org/10.1530/EDM-16-0101 Text en This is an Open Access article distributed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) .
spellingShingle Insight into Disease Pathogenesis or Mechanism of Therapy
Marchetti, Katia Regina
Pereira, Maria Adelaide Albergaria
Lichtenstein, Arnaldo
Paiva, Edison Ferreira
Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma
title Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma
title_full Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma
title_fullStr Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma
title_full_unstemmed Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma
title_short Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma
title_sort refractory hypoglycemia in a patient with functional adrenal cortical carcinoma
topic Insight into Disease Pathogenesis or Mechanism of Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097138/
https://www.ncbi.nlm.nih.gov/pubmed/27857836
http://dx.doi.org/10.1530/EDM-16-0101
work_keys_str_mv AT marchettikatiaregina refractoryhypoglycemiainapatientwithfunctionaladrenalcorticalcarcinoma
AT pereiramariaadelaidealbergaria refractoryhypoglycemiainapatientwithfunctionaladrenalcorticalcarcinoma
AT lichtensteinarnaldo refractoryhypoglycemiainapatientwithfunctionaladrenalcorticalcarcinoma
AT paivaedisonferreira refractoryhypoglycemiainapatientwithfunctionaladrenalcorticalcarcinoma